Tesamorelin, liver fat, and NAFLD in the setting of HIV.,The Lancet HIV

当前位置： X-MOL 学术 › Lancet HIV › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tesamorelin, liver fat, and NAFLD in the setting of HIV.
The Lancet HIV ( IF 12.8 ) Pub Date : 2019-10-11 , DOI: 10.1016/s2352-3018(19)30331-5
Jennifer Audsley ₁ , Joe Sasadeusz ₂ , Sharon R Lewin ₃

Affiliation

Management of abnormal liver function tests and cirrhosis, in the absence of hepatis B or C coinfection and high alcohol intake, has become an important issue in people with HIV on antiretroviral therapy (ART). One of the most common causes for abnormal liver function in both the general population and people living with HIV is non-alcoholic fatty liver disease (NAFLD), which has two forms: non-alcoholic steatohepatitis (NASH) or hepatic steatosis ( ). Between 6% and 35% of people globally have NASH-related cirrhosis, and it is the fastest growing indication for liver transplantation in the USA. In people living with HIV on ART, the prevalence of NAFLD is higher (26–65%) and they can have more severe clinical and biochemical manifestations and a faster rate of liver fibrosis progression. Surprisingly, there are few treatment options available for this very common disease and even fewer have been evaluated in people with HIV.

中文翻译：

Tesamorelin，肝脂肪和NAFLD在HIV的背景下。

在没有乙肝或丙肝合并感染和大量饮酒的情况下，异常肝功能检查和肝硬化的管理已成为艾滋病毒感染者接受抗逆转录病毒疗法（ART）的重要问题。在普通人群和HIV感染者中，最常见的肝功能异常原因之一是非酒精性脂肪肝疾病（NAFLD），其有两种形式：非酒精性脂肪性肝炎（NASH）或肝脂肪变性（）。全球有6％至35％的人患有NASH相关的肝硬化，这是美国肝移植增长最快的适应症。在接受抗逆转录病毒治疗的HIV感染者中，NAFLD的患病率较高（26-65％），他们的临床和生化表现更为严重，肝纤维化进展速度更快。出奇，

更新日期：2019-12-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文